title: [Recombinant interferon alpha-2c in Ph-positive chronic myeloid leukemia. Results of a multicenter phase II study].
abstract: In a Phase II study, 82 patients with Philadelphia chromosome(Ph)-positive chronic myelogenous leukaemia were treated with 3.5 million I.U./d of recombinant interferon alpha-2c (rIFN). 73 patients have so far been evaluated (42 male, 31 female, mean age 50 [12-87] years). At the start of therapy, 10 were in the accelerated phase (group 1) and 63 in the chronic phase, of whom 19 had received previous treatment with cytotoxics (group 2), while the remainder (group 3, n = 44) had received primary treatment with rIFN. There was short-term stabilization in 7 of the 10 group 1 patients, but none had complete haematological or cytogenetic remission. In contrast, the remission rate (complete or partial haematological remission) was 63% in the previously treated (group 2) and 66% in the previously untreated chronic phase patients (group 3). There was a reduction in the proportion of Ph-positive metaphases in 7 group 2 patients (11%) and in 10 group 3 patients (23%). Complete cytogenetic remission has so far been seen in 2 patients. Cytogenetic improvement occurred after 3 months at the earliest, and in some patients only after 12 to 19 months treatment. Differences in response to treatment were related to stage (prognostic staging system of Kantarjian et al.) in group 3 patients: complete or partial haematological remission was seen in 22 out of 25 patients with stage 1 disease, in 4 out of 7 in stage 2, and in only 3 out of 12 in stages 3 and 4.
authors.affiliation: Universitätsklinik für Innere Medizin, Innsbruck.
authors.forename: J
authors.initials: J
authors.lastname: Thaler
authors.forename: T
authors.initials: T
authors.lastname: Kühr
authors.forename: G
authors.initials: G
authors.lastname: Gastl
authors.forename: H
authors.initials: H
authors.lastname: Huber
authors.forename: C
authors.initials: C
authors.lastname: Duba
authors.forename: G
authors.initials: G
authors.lastname: Kemmler
authors.forename: C
authors.initials: C
authors.lastname: Gattringer
authors.forename: T
authors.initials: T
authors.lastname: Fluckinger
authors.forename: D
authors.initials: D
authors.lastname: Niederwieser
authors.forename: H
authors.initials: H
authors.lastname: Seewann
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011994:Recombinant Proteins; D013997:Time Factors
chemical_list: D007370:Interferon Type I; D011994:Recombinant Proteins